Table 3.
Sensitivity analysis.
| Taiwan | UK | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patients | Events | Follow-Up (Person-Years) |
Incidence Rate (per 103 Person-Years) |
Adjusted HR (95% CIs) | Patients | Events | Follow-Up (Person-Years) |
Incidence Rate (per 103 Person-Years) |
Adjusted HR (95% CIs) | |
| Analysis by PS with multivariate adjustment | ||||||||||
| ADT-naïve group | 8745 | 121 | 44,190.8 | 2.74 | Reference | 17,040 | 243 | 97,787.1 | 2.48 | Reference |
| ADT group | 30,900 | 513 | 149,436.5 | 3.43 | 0.98 (0.80, 1.20) | 30,970 | 525 | 150,495.2 | 3.49 | 1.02 (0.87, 1.19) |
| Analysis by PS with IPTW | ||||||||||
| ADT-naïve group | 8780.4 | 156.4 | 42,884.6 | 3.65 | Reference | 17,199 | 296 | 92,189.7 | 3.21 | Reference |
| ADT group | 30,882 | 494.0 | 150,845.5 | 3.27 | 0.91 (0.76, 1.09) | 30,912 | 484 | 156,175.6 | 3.09 | 0.99 (0.86, 1.14) |
| Analysis by PS with SMRW | ||||||||||
| ADT-naïve group | 24,442.8 | 414.5 | 121,389.2 | 3.41 | Reference | 29,596 | 575 | 156,092.1 | 3.68 | Reference |
| ADT group | 30,900 | 513.0 | 149,436.5 | 3.43 | 1.03 (0.90, 1.17) | 30,970 | 525 | 150,495.2 | 3.49 | 0.98 (0.87, 1.10) |
| Cause-specific hazard model | ||||||||||
| ADT-naïve group | 8743 | 121 | 44,181.7 | 2.74 | Reference | 14,949 | 237 | 84,331.1 | 2.81 | Reference |
| ADT group | 8743 | 134 | 44,291.4 | 3.03 | 1.12 (0.88, 1.43) | 14,949 | 220 | 78,765.1 | 2.79 | 1.02 (0.85, 1.23) |
| Sub-distribution hazard model | ||||||||||
| ADT-naïve group | 8743 | 121 | 44,181.7 | 2.74 | Reference | 14,949 | 237 | 84,331.1 | 2.81 | Reference |
| ADT group | 8743 | 134 | 44,291.4 | 3.03 | 0.93 (0.73, 1.20) | 14,949 | 220 | 78,765.1 | 2.79 | 0.85 (0.71,1.02) |
| 1-year landmark period | ||||||||||
| ADT-naïve group | 11,903 | 199 | 80,477.0 | 2.47 | Reference | 15,738 | 283 | 91,334.5 | 3.099 | Reference |
| ADT group | 11,903 | 180 | 67,640.7 | 2.66 | 1.12 (0.95, 1.32) | 15,738 | 275 | 82,845.1 | 3.319 | 1.12 (0.95, 1.32) |
| 2-year landmark period | ||||||||||
| ADT-naïve group | 9382 | 161 | 70,109.1 | 2.30 | Reference | 12,885 | 244 | 72,094.0 | 3.38 | Reference |
| ADT group | 9382 | 138 | 61,166.0 | 2.26 | 1.16 (0.93, 1.47) | 12,885 | 218 | 66,517.8 | 3.28 | 1.003 (0.84, 1.20) |
ADT: androgen deprivation therapy; CI: confidence interval; HR: hazard ratio; IPTW: inverse-probability-of-treatment weighting; PS: propensity score; SMRW: standardized mortality ratio weighting.